U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039370) titled 'Molecular Signatures of TMS Response in Treatment-Resistant Depression' on May 31.
Brief Summary: Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will a...